What's Happening?
Mondego Bio, a biotechnology company, has initiated a first-in-human Phase 1 clinical study for MB-388, an oral dual PTPN2/PTPN1 inhibitor. This investigational drug is designed to overcome resistance to cancer immunotherapy by acting on both tumor cells
and immune cells. The Phase 1a study is a randomized, double-blind, placebo-controlled trial evaluating single and multiple ascending doses of MB-388 in healthy volunteers. Its primary objectives are to assess safety and tolerability, characterize pharmacokinetics (PK), and measure target engagement using blood-based pharmacodynamic (PD) biomarkers. Preclinical studies showed MB-388 to have superior properties compared to other inhibitors in its class, including higher oral exposure and longer target coverage, along with strong selectivity and favorable safety margins.
Why It's Important?
The initiation of this clinical study for MB-388 is significant because it addresses a critical challenge in cancer treatment: resistance to immunotherapy. Many patients do not respond to or eventually develop resistance to existing checkpoint inhibitors, limiting the long-term effectiveness of these life-saving treatments. By targeting PTPN2 and PTPN1, MB-388 aims to restore interferon-gamma signaling, enhance antigen presentation, and boost T-cell and natural killer (NK) cell function, thereby making tumors more susceptible to immune attack. If successful, MB-388 could significantly expand the population of patients who benefit from immunotherapy, improving outcomes for those with advanced solid tumors who have progressed on standard therapies. This could represent a major advancement in oncology, offering a new therapeutic avenue for difficult-to-treat cancers.
What's Next?
Mondego Bio expects initial human PK and PD data from the Phase 1a study in healthy volunteers by December 2026. Following this, the company plans to begin a Phase 1b study in January 2027, which will enroll patients with advanced solid tumors who have progressed on or after standard therapy, including those previously treated with checkpoint inhibitors. The Phase 1b study will first evaluate MB-388 as monotherapy, followed by a combination run-in with PD-(L)1 blockade. A readout from the combination dose escalation is planned for December 2027. These upcoming milestones will provide crucial insights into the drug's efficacy and safety in cancer patients, guiding its further clinical development.
Beyond the Headlines
The development of drugs like MB-388 highlights a growing understanding of the complex mechanisms underlying cancer immunotherapy resistance. By targeting specific phosphatases (PTPN2/PTPN1), researchers are moving towards more nuanced approaches to 're-sensitize' tumors to immune attack. This strategy reflects a broader trend in oncology to develop combination therapies that overcome tumor evasion tactics, rather than relying solely on single-agent treatments. The success of such inhibitors could not only improve patient survival but also reduce the economic burden of prolonged, ineffective treatments. Furthermore, it underscores the importance of basic science research in identifying novel therapeutic targets that can translate into meaningful clinical benefits for cancer patients.
